期刊文献+

临床分离大肠埃希菌573株耐药性分析 被引量:1

下载PDF
导出
摘要 目的:调查我院大肠埃希菌耐药情况,指导临床用药。方法:收集我院2002-2004年临床分离573株大肠埃希菌,使用K irby-Bauer纸片琼脂扩散法测定其对16种抗菌药的抑菌环直径,按美国临床实验室标准委员会(N C C LS)2004年标准判读结果。结果:IC U、非IC U病房和门诊病人分离菌耐药率最低的前5种抗菌药依次为亚胺培南(0%)、美罗培南(0%)、哌拉西林-他唑巴坦(3.3%~4.8%)、头孢他啶(2.2%~9.5%)和阿米卡星(2.2%~10.8%);耐药率最高的前5种抗菌药依次为复方新诺明(63.6%~87.8%)、哌拉西林(66.7%~86.1%)、环丙沙星(43.5%~85.7%)、氨苄西林-舒巴坦(36.7%~74.4%)和庆大霉素(46.3%~71.1%)。IC U和非IC U病房分离菌对头孢噻肟、头孢曲松的耐药率高达38.1%~66.7%;IC U分离菌对氨苄西林-舒巴坦、头孢噻肟、头孢曲松、氨曲南、环丙沙星、庆大霉素和复方新诺明的耐药率显著高于非IC U病房和门诊分离菌(P<0.05);IC U、非IC U病房和门诊病人分离菌E SB Ls检出率分别为73.8%、41.6%和21.7%;呼吸道、无菌体液、泌尿道及其它部位分离菌E SB Ls检出率分别为73.8%、47.8%、31.1%和54.3%;除亚胺培南和美罗培南外,产E SB Ls菌对常用β-内酰胺类和非β-内酰胺类抗菌药的敏感性均明显低于不产E SB Ls菌(P<0.01)。结论:我院临床分离大肠埃希菌对多种抗菌药的耐药率较高,应加强细菌耐药的监控。
出处 《实用医学杂志》 CAS 2006年第3期341-343,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献5

  • 1BRADFORD P A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat [J]. Clin Microbiology Reviews, 2001, 14(4): 933 -951.
  • 2BUSH K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy [J]. Clin Infect Dis,2001,32(7): 1085 - 1089.
  • 3KARLOWSKY J A, JONES M E, THORNSBERRY C, et al. Trends in antimicroblal susceptibilities among Entembacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 [J].Antimicrob Agents Chemother, 2003, 47(5): 1672 - 1680.
  • 4陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504
  • 5朱德妹,汪复,张婴元.2003年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(1):4-12. 被引量:147

二级参考文献30

  • 1朱德妹,汪复,胡付品,吴湜,张婴元.2002年上海地区医院细菌耐药性监测[J].中华传染病杂志,2004,22(3):154-159. 被引量:63
  • 2熊自忠,朱德妹,汪复,张婴元.CTX-M-14和CTX-M-24编码基因的检测及其功能表达[J].中华医学杂志,2004,84(17):1454-1459. 被引量:15
  • 3National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Testing,Twelfth Informational Supplement[S]. 2003 ,M100-S13.
  • 4Jae-Hoon Song. Pneumococcal Resistance to Beta-Lactams and Macrolides[C]. International Symposium on Antimicrobial Agents and Resistance, 2003,30-33.
  • 5Center for diseases prevention &epidemiology. oregon health division. Vancomycin-resistant enterococcal infections[J]. C D summary, 1997,46:1.
  • 6EARSS Annual Report 2002[EB/OL]. http://www. earss.rivm. nl.
  • 7Wang H, KelKar S, Wu W, etal, Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases:prevalence of CTX-M-3 at a hospital in China[J]. Antimicrob Agents chemother, 2003,47: 790-793.
  • 8Chanawong A,MZali FH, Heritage J. et al. Three cefortaximases, CTX-M-9, CTX-M-13 and CTX-M-14, among Enterobacteriaceae in the People's Republic of China[J]. Antimicrob Agents Chemother, 2002,46: 630-637.
  • 9Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 10Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.

共引文献635

同被引文献7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部